4//SEC Filing
MCCOLLUM JAMES W 4
Accession 0001815776-24-000028
CIK 0001815776other
Filed
Mar 24, 8:00 PM ET
Accepted
Mar 25, 8:42 PM ET
Size
13.9 KB
Accession
0001815776-24-000028
Insider Transaction Report
Form 4
MCCOLLUM JAMES W
Director
Transactions
- Award
Warrant (right to buy)
2024-03-21+6,575→ 6,575 total(indirect: By Trust)Exercise: $10.64From: 2020-10-30Exp: 2027-10-30→ Common Stock (6,575 underlying) - Award
Common Stock
2024-03-21+95,034→ 95,034 total - Award
Common Stock
2024-03-21+477,600→ 477,600 total(indirect: By Trust) - Award
Common Stock
2024-03-21$15.03/sh+16,633$249,992→ 494,233 total(indirect: By Trust) - Award
Stock Option (right to buy)
2024-03-21+27,000→ 27,000 totalExercise: $15.05Exp: 2034-03-20→ Common Stock (27,000 underlying)
Footnotes (4)
- [F1]Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of outstanding shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement.
- [F2]Shares issued upon the closing of the private placement financing under the Subscription Agreement by and among the Issuer, the Reporting Person and the other purchasers party thereto, dated as of November 14, 2023, pursuant to which, immediately following the closing of the transactions contemplated by the Merger Agreement, such purchasers purchased an aggregate of 3,559,565 shares of Common Stock at a price of $15.0299 per share for aggregate gross proceeds to the Issuer of approximately $53.5 million, as more fully described in the Issuer's reports filed with the Securities and Exchange Commission.
- [F3]Warrant assumed in connection with the closing of the transactions contemplated by the Merger Agreement, in exchange of an outstanding warrant to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement.
- [F4]Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024.
Documents
Issuer
LENZ Therapeutics, Inc.
CIK 0001815776
Entity typeother
Related Parties
1- filerCIK 0001200889
Filing Metadata
- Form type
- 4
- Filed
- Mar 24, 8:00 PM ET
- Accepted
- Mar 25, 8:42 PM ET
- Size
- 13.9 KB